Phase 1 reset — Weeks 1-4

The first four weeks are not about fat loss. They are about taking the load off a pancreas that has been firing insulin into deaf tissue for years, while simultaneously rebooting the mitochondrial machinery that was supposed to burn the glucose in the first place. These two problems compound. High insulin demand burns out beta cells, and broken mitochondria mean the glucose insulin shuttles into the cell has nowhere productive to go, so it gets stored as fat, which worsens insulin resistance, which raises insulin demand. Phase 1 attacks both sides of that loop simultaneously. [short pause] Here is what is actually happening at the cellular level. Tirzepatide is a dual G-L-P 1 slash G-I-P RECEPTOR AGONIST. Single-receptor G-L-P 1 agonists — semaglutide, liraglutide — work primarily through appetite suppression and delayed gastric emptying. The practitioner corpus describes the hemoglobin A1c nadir at roughly twenty weeks on semaglutide, with effect mediated through weight loss and slowed glucose entry into the bloodstream. Tirzepatide adds the G-I-P arm. G-I-P — glucose-dependent insulinotropic polypeptide — does two things that G-L-P 1 alone cannot. It improves muscle nutrient partitioning, meaning glucose preferentially routes into muscle instead of fat storage, and it amplifies the glucose-dependent insulin response at the pancreatic beta cell. Net effect: lower insulin demand AND better disposal of what insulin you do release. Critically, G-I-P's insulin-secreting effect is GLUCOSE-DEPENDENT. The corpus is explicit on this. G-I-P infused at supra-physiological doses produces an early post-meal insulin bump, but does not stimulate glucagon secretion when glucose is below five point five millimoles per liter. Translation: tirzepatide does not push insulin when it isn't needed. This is why hypoglycemia is rare on tirzepatide in non-diabetic users — the mechanism is glucose-gated. [short pause] MOTS-c attacks the other half of the loop. MOTS-c is a sixteen-amino-acid mitochondrial-derived peptide that activates AMPK. AMPK is the cellular fuel gauge — when it senses low A-T-P, it forces the cell to switch from glucose-storage mode to glucose-burning mode. The practitioner corpus describes MOTS-c as the EXERCISE MIMETIC because it triggers the same metabolic cascades as vigorous training: fatty acid oxidation, increased glucose uptake at the muscle, restored metabolic flexibility. In the insulin-resistance context, this is the lever that converts the cell from glucose-hoarding to glucose-burning. The stack is logical. Tirzepatide reduces the demand on insulin — less glucose arriving, better partitioning. MOTS-c restores the capacity of the cell to actually use the glucose that does arrive. One without the other is half a protocol. [short pause] Now the Phase 1 prescription. There are four compounds. First, tirzepatide. Start at two point five milligrams subcutaneous in the abdomen, once weekly, for Weeks 1 and 2. Escalate to five milligrams in Week 3 only if Week 2 nausea is manageable. This sits in the Clinical evidence lane. The practitioner corpus is explicit: longer dose-escalation regimens are associated with better tolerance for nausea and vomiting. Do NOT skip the ramp. Second, MOTS-c. Five milligrams subcutaneous in the abdomen, rotating sites, three times per week — Monday, Wednesday, and Friday. This sits in the Expert evidence lane. Conservative starting protocol per the corpus. Run a four-week cycle, then a four-week rest before Phase 2 re-introduction. Escalate to ten milligrams only if Week 2 to 3 energy response is clean. Third, methylene blue. Zero point five to one milligram, oral, daily, in the morning. Also Expert lane. Run it for two weeks BEFORE introducing MOTS-c, and continue through Phase 1. It stabilizes the electron transport chain, reduces baseline reactive oxygen species, and creates the substrate window where MOTS-c amplifies output instead of overwhelming damaged mitochondria. Fourth, BPC-157. Five hundred micrograms subcutaneous, daily. Expert lane. Mitochondrial membrane repair. The corpus specifically calls for adding BPC-157 when MOTS-c needs gut and cellular substrate support. Drop to every-other-day after Week 4 if response is clean. [short pause] Reconstitution math for MOTS-c on a five-milligram vial. Reconstitute with two milliliters bacteriostatic water. Each zero point two milliliters equals zero point five milligrams, so a five-milligram dose draws the full two milliliters. For a two point five milligram test dose, draw one point zero milliliters — that's fifty units on a U-one hundred insulin syringe. For injection-site rotation: tirzepatide and MOTS-c both go subcutaneous in the abdomen. Run tirzepatide on the left side, MOTS-c on the right, rotating sites at least two inches between injections to avoid lipohypertrophy. [short pause] Here is what you should feel. The substrate is specific about the temporal profile, and it does not match the G-L-P 1 shreds fat in week one social media narrative. Week 1: nausea is the dominant signal. The practitioner corpus describes the G-L-P 1 slash G-I-P class consistently producing nausea, vomiting, and reduced appetite in the first seven to fourteen days. Eat smaller meals, slow down, no fatty or greasy food. MOTS-c at this stage is subtle. You may notice cleaner energy on dose days — Monday, Wednesday, Friday. Week 2: nausea begins to plateau if you held at two point five milligrams. Hunger is noticeably lower. Cravings — especially for sugar and ultra-processed food — drop sharply. On MOTS-c, energy on dose days is more consistent and mid-afternoon crashes start to soften. Week 3: tirzepatide escalates to five milligrams. Expect a second small nausea wave for two to three days. Fasting glucose may start moving — this is the lagging marker, don't expect dramatic shifts yet. Post-meal glucose excursions should already be visibly lower if you're tracking with a continuous glucose monitor. Week 4: steady state. Energy stable. Appetite predictably suppressed. Sleep often deeper — the corpus notes MOTS-c's downstream effects on metabolic flexibility translate into improved overnight glucose stability, which manifests as fewer three A-M wake-ups. End of Phase 1: pull labs. [short pause] Now, what is NOT happening yet. Set these expectations correctly so you do not abandon the protocol or escalate doses prematurely. Hemoglobin A1c will barely move. Hemoglobin A1c is a ninety-day rolling average. At Week 4 you are looking at less than thirty percent of the window having been on protocol. Don't draw hemoglobin A1c at Week 4 expecting validation — fasting insulin and post-meal glucose excursions are the leading markers. Hemoglobin A1c is the lagging confirmation, drawn at Week ten. Weight loss is secondary, not primary. The practitioner corpus is consistent: Phase 1 is metabolic infrastructure work, not caloric deficit work. Some weight will move — three to eight pounds is typical, mostly water and glycogen. Aggressive scale loss is a Phase 2 phenomenon. MOTS-c is not a stimulant. If you are expecting caffeine-like energy on dose days, you will be disappointed and likely escalate dose prematurely. The corpus is explicit: MOTS-c works upstream and slowly. Subtle is the correct signal. Do not run this on a zero-carb diet. The corpus calls this out directly for the G-L-P 1 slash G-I-P class — running a ketogenic diet on tirzepatide has produced documented cases of euglycemic ketoacidosis. Maintain eighty to one hundred twenty grams of clean carbohydrates daily — rice, potatoes, fruit — around training and your largest meal. Tirzepatide will suppress appetite enough that you have to be deliberate about this. Paradoxical fatigue is a stop-signal, not a push-through signal. If Week 1 to 2 energy on MOTS-c gets WORSE instead of cleaner, your mitochondria are too inflamed for AMPK activation. The corpus instructs: stop MOTS-c, extend the methylene-blue-only prep phase for another two to four weeks, retest C-R-P, then re-introduce. This is not a failure — it is the protocol functioning as a diagnostic. Hypoglycemia is unlikely but possible if stacking with insulin or sulfonylureas. Tirzepatide alone is glucose-dependent. Combined with exogenous insulin or sulfonylurea drugs, the risk shifts. If you are on either, that is the conversation to have before Day 1, not Week 3. [short pause] End-of-Phase-1 labs to pull at Day twenty-eight: fasting glucose, fasting insulin — calculate HOMA-I-R — triglyceride to H-D-L ratio, high-sensitivity C-R-P, and free T-3. Compare to the baseline you pulled before Day 1. The triglyceride to H-D-L ratio and fasting insulin are the early-mover markers — they will shift well before hemoglobin A1c does. The practitioner corpus describes this protocol consistently across high-volume clinical practice. Track the leading markers, not the lagging ones, and adjust from data.